英夫利西单抗治疗中重度银屑病的疗效及安全性研究

Efficacy and safety of infliximab in the treatment of moderate to severe psoriasis

目的:探讨英夫利西单抗治疗中重度银屑病的疗效与安全性。方法:对传统治疗效果不佳的中重度银屑病患者,于第0、2、6、14、22、30、38、46、54周给予英夫利西单抗5 mg·kg-1静脉滴注一次,观察并记录患者在第0、2、6、14、22、30、38、46、54周时的PASI评分及药品不良反应。结果:13例中重度银屑病患者在第2、6、14、22、30、38、46、54周时,PASI75分别为0、30.77%、76.92%、69.23%、69.23%、69.23%、46.15%、61.54%;PASI90分别为0、7.70%、23.08%、30.77%、23.08%、15.38%、15.38%、15.38%;PASI95分别为0、7.70%、7.70%、15.38%、7.70%、7.70%、0、7.70%。54周时患者的白细胞、红细胞、血红蛋白、血小板、天门冬氨酸氨基转移酶、肌酐及血沉与0周时相比无明显上升及下降;CRP数值较0周时明显下降;丙氨酸氨基转移酶、尿素较0周时明显上升,但在第54周时指标平均值均未超出正常范围。结论:英夫利西单抗在治疗中重度银屑病起效迅速、疗效肯定、54周内安全性良好,但更长期疗效及安全性仍有待进一步研究。

Objective:To investigate the efficacy and safety of infliximab in the treatment of moderate to severe psoriasis.Methods:Patients with moderate to severe psoriasis who had poor results with traditional treatment were given intravenous infusion of infliximab 5 mg·kg-1 at 0,2,6,14,22,30,38,46,and 54 weeks.The patient’s PASI scores and adverse drug reaction at 0,2,6,14,22,30,38,46 and 54 weeks were observed and recorded.Results:At 2,6,14,22,30,38,46 and 54 weeks,PASI75 of 13 patients with moderate to severe psoriasis was 0,30.77%,76.92%,69.23%,69.23%,69.23%,46.15%and 61.54%respectively;PASI90 of them was 0,7.70%,23.08%,30.77%,23.08%,15.38%,15.38%,15.38%respectively;PASI95 of them was 0,7.70%,7.70%,15.38%,7.70%,7.70%,0,7.70%respectively.At 54 weeks,white blood cells,red blood cells,hemoglobin,platelets,aspartate aminotransferase,creatinine and erythrocyte sedimentation of 13 patients did not significantly increase or decrease compared with those at 0 weeks while CRP values obviously decreased and alanine aminotransferase,urea significantly increased compared with those of 0 week.But the average values of the above indexes at 54 weeks were all in the normal range.Conclusion:Infliximab had a rapid onset,a positive effect,good safety for the treatment of moderate to severe psoriasis within 54 weeks.But the longer-term efficacy and safety of infliximab remains to be further studied.